Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3.

Parainfluenza viruses. Clin Microbiol Rev (2003) 2.39

Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol (2002) 1.34

Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol (1999) 1.33

Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol (1991) 1.24

Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol (2001) 1.24

Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus. J Virol (1990) 1.08

Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. J Clin Microbiol (1992) 0.98

Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene. J Virol (1996) 0.88

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine (2013) 0.87

Current approaches to the development of vaccines effective against parainfluenza viruses. Bull World Health Organ (1988) 0.85

Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain. J Virol (1995) 0.84

The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children. Pediatr Infect Dis J (2011) 0.81

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis (1996) 5.14

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA (1999) 3.53

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med (1989) 3.16

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90

Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis (1982) 2.17

Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol (1987) 2.06

Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection. Infect Immun (1978) 1.96

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis (1995) 1.83

Experimental respiratory syncytial virus infection of four species of primates. J Med Virol (1977) 1.74

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics (2001) 1.70

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67

Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis (1993) 1.62

Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun (1982) 1.61

Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. J Infect Dis (1988) 1.58

Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res (1992) 1.51

Palmitoylation of the influenza A virus M2 protein. Virology (1990) 1.51

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47

Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother (1991) 1.43

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med (1991) 1.43

Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: I. Viral shedding, immunologic response, and associated illness. J Med Virol (1978) 1.42

Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA (1995) 1.40

Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr (1992) 1.38

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine (2000) 1.38

Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun (1994) 1.35

Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens. Antimicrob Agents Chemother (1990) 1.35

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis (1998) 1.33

Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol (1990) 1.31

Experimental respiratory syncytial virus pneumonia in cebus monkeys. J Med Virol (1978) 1.30

Temperature-sensitive mutants of influenza A virus. XIV. Production and evaluation of influenza A/Georgia/74-ts-1[E] recombinant viruses in human adults. J Infect Dis (1977) 1.29

Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J Infect Dis (1984) 1.28

Nosocomial influenza B virus infection in the elderly. Ann Intern Med (1982) 1.25

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis (1992) 1.25

Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassay. J Clin Microbiol (1994) 1.25

Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol (1991) 1.24

Serological diagnosis of influenza B virus infection: comparison of an enzyme-linked immunosorbent assay and the hemagglutination inhibition test. J Clin Microbiol (1982) 1.23

Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis (1996) 1.21

Further characterization of the complementation group B temperature-sensitive mutant of respiratory syncytial virus. J Virol (1977) 1.21

Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J Gen Virol (1994) 1.20

Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol (1982) 1.19

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis (1996) 1.19

Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis (1998) 1.18

Mucosal bacille calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses. Clin Infect Dis (2000) 1.17

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis (1996) 1.16

A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination. J Lab Clin Med (1999) 1.15

Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children. J Infect Dis (1986) 1.12

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses (1998) 1.12

Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin". J Infect Dis (1994) 1.09

Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol (1995) 1.08

Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: II. Genetic analysis of virus recovered during infection. J Med Virol (1978) 1.05

Live attenuated influenza A virus vaccines in children: results of a field trial. J Infect Dis (1984) 1.03

Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis (1993) 1.01

A single-season epidemic with respiratory syncytial virus subgroup B2 during 10 epidemic years, 1978 to 1988. J Clin Microbiol (1991) 1.01

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1999) 0.98

Epidemiology of severe respiratory syncytial virus infections in Huntington, West Virginia. W V Med J (1981) 0.98

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis (2000) 0.98

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J (2001) 0.98

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis (2012) 0.97

Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production. J Infect Dis (2001) 0.97

Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. J Clin Microbiol (1986) 0.97

Impact of viral respiratory diseases on infants and young children in a rural and urban area of southern West Virginia. Am J Epidemiol (1983) 0.97

Superiority of tissue-culture-grown antigens over egg-grown antigens for serologic diagnosis of influenza B virus infections. J Med Virol (1986) 0.97

Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand J Infect Dis (1991) 0.96

From the National Institutes of Health: report of a workshop on respiratory syncytial virus and parainfluenza viruses. J Infect Dis (1978) 0.96

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1997) 0.96

HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network. Vaccine (1995) 0.95

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis (1996) 0.95

Male genital tuberculosis: a review of the literature with instructive case reports. Rev Infect Dis (1985) 0.94

Evaluation of cold-adapted and temperature-sensitive mutants of parainfluenza virus type 3 in weanling hamsters. J Med Virol (1984) 0.92

Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA (1994) 0.92

Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. J Clin Microbiol (1988) 0.91

Isolation and characterization of further defective clones of a temperature sensitive mutant (ts-1) of respiratory syncytial virus. Arch Virol (1977) 0.91

Human-rhesus reassortant rotavirus vaccines: safety and immunogenicity in adults, infants, and children. J Infect Dis (1988) 0.90

Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis (1994) 0.90

A review of adenoviruses in the etiology of acute hemorrhagic cystitis. J Urol (1976) 0.88

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. J Infect Dis (1994) 0.88

Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene. J Virol (1996) 0.88

Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest (1991) 0.87

Prospects for prevention of bronchiolitis caused by respiratory syncytial virus. Pediatr Res (1977) 0.87

Cause of acute hemorrhagic cystitis in children. Am J Dis Child (1973) 0.87

Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS (1999) 0.86

Characteristics of a population volunteering for human immunodeficiency virus immunization. NIAID AIDS Clinical Trials Network. Int J STD AIDS (1990) 0.86

Comparison of enzyme-linked immunosorbent assay and neutralization techniques for measurement of antibody to respiratory syncytial virus: implications for parenteral immunization with live virus vaccine. Infect Immun (1982) 0.86

Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother (1987) 0.86

Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies. Vaccine (1999) 0.85

Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus. Virus Res (2001) 0.85

HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. Clin Exp Immunol (1994) 0.84

Clinical and serologic responses to acellular pertussis vaccine in infants and young children. Am J Dis Child (1987) 0.84

Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain. J Virol (1995) 0.84

Occurrence, characteristics, and patterns of HIV-1 and HIV-2 western blot indeterminate sera in low risk populations in West Virginia and pre-AIDS Africa. Am J Trop Med Hyg (1990) 0.84

Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis (1994) 0.83

Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J Infect Dis (1988) 0.83

Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children. J Clin Microbiol (1992) 0.83

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network. Vaccine (1992) 0.83

HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res Hum Retroviruses (2001) 0.83

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1999) 0.82

Identification by immunofluorescence of adenoviral antigen in exfoliated bladder epithelial cells from patients with acute hemorrhagic cystitis. Proc Soc Exp Biol Med (1974) 0.82

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Vaccine (1998) 0.82

Fatal coxsackievirus B4 infection in a neonate. South Med J (1985) 0.81

Synthesis and antiviral activity of metabolites of rimantadine. J Med Chem (1990) 0.80

Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network. J Clin Microbiol (1992) 0.80